EcoDrugPlus

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSBBBG00000009367
Gene Symbol: PSMA5
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSBBBG00000009515
Gene Symbol: PSMA6
3 Cross references
268 Possible Orthologues:

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSBBBG00000023734
Gene Symbol: PSMA7
2 Cross references
150 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSBBBG00000019972
Gene Symbol: PSMA8
3 Cross references
198 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSBBBG00000007698
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSBBBG00000008328
Gene Symbol: PSMB10
3 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSBBBG00000021588
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSBBBG00000022529
Gene Symbol: PSMB3
3 Cross references
251 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSBBBG00000013410
Gene Symbol: PSMB4
3 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSBBBG00000014083
Gene Symbol: PSMB6
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSBBBG00000015071
Gene Symbol: PSMB7
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSBBBG00000015244
Gene Symbol: PSMB8
3 Cross references
221 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).